Quick Overview: Josep M. Llovet, MD, Mount Sinai, and Richard S. Finn, MD, University of California, Los Angeles, consider the available data and ... Recommendations for managing patients with metastatic renal cell carcinoma who are resistant to A roundtable discussion, moderated by Brian Rini, MD, of the Vanderbilt-Ingram Cancer Center, focused on treatment ...
Io Io Vs Io Vegf - Detailed Overview & Context
Josep M. Llovet, MD, Mount Sinai, and Richard S. Finn, MD, University of California, Los Angeles, consider the available data and ... Recommendations for managing patients with metastatic renal cell carcinoma who are resistant to A roundtable discussion, moderated by Brian Rini, MD, of the Vanderbilt-Ingram Cancer Center, focused on treatment ... Implications of more recent data on the use of a Alexander Drilon, MD, and Justin Gainor, MD, consider the approach of adding Daniel George, MD; Richard W. Joseph, MD; Toni Choueiri, MD; and Walter Stadler, MD, review the factors to consider when ...
Topics also include: Efficacy and safety of Dr Sharma is also hopeful new immunotherapy combinations ( Neeraj Agarwal, MD, discusses the rationale for choosing a TKI therapy over dual nivolumab/ipilimumab therapy, including safety ... Factors that influence clinicians' decisions to treat with a A roundtable discussion, moderated by Brian Rini, MD, discussed the latest data from the American Society of Clinical Oncology ... This video is intended for U.S. healthcare professionals only. How may transarterial chemoembolization (TACE), vascular ...
... discusses real-world clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) in current immune-oncology ( Thomas Hutson, DO, PharmD, FACP; James J. Hsieh, MD, PhD; and Martin H. Voss, MD, explain the clinical rationale for ... David A. Braun, MD, PhD, Yale School of Medicine, New Haven, CT, discusses the treatment options for patients who have ... Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses ... Bradley McGregor, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses prospects for various therapeutic ... ... managed although that's not particularly calm as common as grade 1
